The First Affiliated Hospital of Zhengzhou University: Carcinoma trials

The registry lists 15 Carcinoma studies with The First Affiliated Hospital of Zhengzhou University as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs TherapyNot yet recruitingNCT06746961Phase 1/2
• IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Not yet recruitingNCT06078657Phase 2
• Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingNCT05896787Phase 2
• Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaNot yet recruitingNCT05189184Phase 2
• Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical StudyStatus unknownNCT05381636Phase 2
• Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT05265962Phase 2
• Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Active, not recruitingNCT05038813Phase 2
• Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT04984018Phase 2
• A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT04533490Phase 2
• The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCCStatus unknownNCT03917966Phase 2
• A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCCStatus unknownNCT03817658Phase 2
• Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03766178Phase 2
• Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell CarcinomaStatus unknownNCT03387904Phase 2
• Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03193424Phase 2
• A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment FailureStatus unknownNCT02772029Phase 1/2